logo-loader

Crescita Therapeutics Signs Pliaglis Out-Licensing Agreement with Cantabria Labs

Published: 17:12 01 May 2019 EDT

Crescita Therapeutics (TSE:CTX-OTC:CFFTF) President and CEO Serge Verreault joined Steve Darling from Proactive Investors Vancouver to discuss the dermatology company signing a big deal with Cantabria Labs for their product Pliaglis. 

Verreault telling Proactive how much that is worth to the company and which markets the deal opens up.

Atlantic Lithium set to hit several milestones at Ewoyaa

Atlantic Lithium Ltd (AIM:ALL, OTCQX:ALLIF, ASX:A11) head of business development and chief geologist Len Kolff sits down with Jonathan Jackson in the Proactive studio to recap the mining lease granted for the Ewoyaa Lithium Project in Ghana and what this means for the company. The lease has...

4 minutes ago